{
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166182844",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166182844",
    "name" : "Annotation of DPWG Guideline for simvastatin and SLCO1B1",
    "cancerGenome" : false,
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1450415247,
      "date" : "2019-05-27T00:00:00-07:00",
      "description" : "Annotation current with November 2018 DPWG Guideline release",
      "type" : "Update",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15102465","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15102465,"resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","title":"Dutch Pharmacogenetics Working Group Guidelines November 2018","sameAs":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","type":"Web Page","xrefs":[{"@id":"https://pharmgkb.org/crossReference/url/https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1450415575,"resource":"URL","resourceId":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf","_url":"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf"}]} ],
    "recommendation" : true,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/variant/PA166154579",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166154579",
      "symbol" : "rs4149056",
      "name" : "rs4149056",
      "version" : 3
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA451363",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA451363",
      "name" : "simvastatin",
      "version" : 20
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA134865839",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA134865839",
      "symbol" : "SLCO1B1",
      "name" : "solute carrier organic anion transporter family member 1B1",
      "version" : 46
    } ],
    "source" : "Dutch Pharmacogenetics Working Group",
    "summaryMarkdown" : {
      "id" : 1450415244,
      "html" : "<p>Choose an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>\n",
      "version" : 0
    },
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1450415245,
      "html" : "<h3 id=\"november-2018-guideline\">November 2018 Guideline</h3>\n<p>The Royal Dutch Pharmacists Association - Pharmacogenetics Working Group has evaluated therapeutic dose recommendations for simvastatin based on SLCO1B1 genotype.  They recommend choosing an alternative for patients with the SLCO1B1 521 CC or TC (rs4149056) genotype and consider any additional risk factors for statin-induced myopathy.  If an alternative is not an option for patients with the 521 TC genotype, avoid simvastatin doses exceeding 40 mg/day and advise the patient to contact their doctor in the event of muscle symptoms.</p>\n<p><em>Wording in table taken from <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf\" target=\"_blank\">https://www.knmp.nl/downloads/pharmacogenetic-recommendations-november-2018.pdf</a></em></p>\n<table class=\"table\">\n<thead>\n<tr><th>Allele/Genotype/Phenotype</th><th>Drug</th><th>Description</th><th>Recommendation</th></tr>\n</thead>\n<tbody>\n<tr><td>512 CC</td><td>simvastatin</td><td>The genetic polymorphism leads to reduced simvastatin transport to the liver. This increases simvastatin plasma concentrations and therefore the risk of myopathy.</td><td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.</td></tr>\n<tr><td>512 TC</td><td>atorvastatin</td><td>The genetic polymorphism may lead to reduced simvastatin transport to the liver. This may increase simvastatin plasma concentrations and therefore the risk of myopathy.</td><td>1. Choose an alternative. Consider any additional risk factors for statin-induced myopathy. Rosuvastatin and pravastatin are influenced to a lesser extent by SLCO1B1 polymorphisms. They are also not influenced by CYP3A4 inhibitors such as amiodarone, verapamil and diltiazem. Fluvastatin is not influenced by SLCO1B1 polymorphisms or CYP3A4 inhibitors.<br/>2. If an alternative is not an option:<br/>1. Avoid simvastatin doses exceeding 40 mg/day<br/>2. Advise the patient to contact their doctor in the event of muscle symptoms.</td></tr>\n</tbody>\n</table>\n<p><a rel=\"noopener noreferrer\" href=\"https://www.g-standaard.nl/risicoanalyse/B0004056.PDF\" target=\"_blank\">Read for more information about this recommendation</a>, <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Read about gene information from DPWG</a></p>\n",
      "version" : 0
    },
    "userId" : "lgong",
    "version" : 0,
    "xrefs" : [ ]
  }
}